| Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance. | Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance.
Peng G, Wang C, Wang H, Qu M, Dong K, Yu Y, Jiang Y, Gan S, Gao X., Free PMC Article | 02/15/2023 |
| miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma. | miR-188-5p and Host MALAT1 Regulate RBE Cell Migration, Invasion, and Apoptosis via Up-regulating PSMD10 in Cholangiocarcinoma.
Yin Z, Wang J, Li T, Ma L, Kang J, Liu G. | 02/11/2023 |
| Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10. | Hsa-miR-1248 suppressed the proliferation, invasion and migration of colorectal cancer cells via inhibiting PSMD10.
Wang C, Wang B, Liang W, Zhou C, Lin W, Meng Z, Wu W, Wu M, Liao Y, Li X, Zhao J, He Y., Free PMC Article | 09/3/2022 |
| Helicobacter pylori and Epstein-Barr Virus Coinfection Stimulates Aggressiveness in Gastric Cancer through the Regulation of Gankyrin. | Helicobacter pylori and Epstein-Barr Virus Coinfection Stimulates Aggressiveness in Gastric Cancer through the Regulation of Gankyrin.
Kashyap D, Baral B, Jakhmola S, Singh AK, Jha HC., Free PMC Article | 02/5/2022 |
| Increased Expression of Gankyrin and Stemness Factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients. | Increased Expression of Gankyrin and Stemness Factor Oct-4 are Associated with Unfavorable Clinical Outcomes and Poor Benefit of Tamoxifen in Breast Carcinoma Patients.
Jahangiri R, Mosaffa F, EmamiRazavi A, Gharib M, Jamialahmadi K. | 04/13/2021 |
| Gankyrin promotes osteosarcoma tumorigenesis by forming a positive feedback loop with YAP. | Gankyrin promotes osteosarcoma tumorigenesis by forming a positive feedback loop with YAP.
Cheng L, Wu B, Zhang L, Bian E, An R, Yu S, Liu W, Xiong Z. | 02/6/2021 |
| findings revealed that miR-3619-5p inhibits cancer cell proliferation by targeting PSMD10, and miR-3619-5p as a potential therapeutic target for the treatment of liver cancer | Inhibiting effect of MicroRNA-3619-5p/PSMD10 axis on liver cancer cell growth in vivo and in vitro.
Hao P, Yue F, Xian X, Ren Q, Cui H, Wang Y. | 08/1/2020 |
| 38 (72%) colorectal cancer (CRC) patients had increased gankyrin expression in tumor cells. The enhanced gankyrin expression in tumor cells was associated with unfavorable progression-free survival and could serve as a biomarker to predict therapeutic response in patients with metastatic CRC. | Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer.
Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Nakagawa K, Kudo M. | 02/29/2020 |
| Results uncovered that Gankyrin functions as an essential regulator in glycolysis and glutaminolysis via activation of beta-catenin/c-Myc to promotes tumorigenesis, metastasis and drug resistance in human hepatocellular carcinoma. | Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating β-catenin/c-Myc signaling in human hepatocellular carcinoma.
Liu R, Li Y, Tian L, Shi H, Wang J, Liang Y, Sun B, Wang S, Zhou M, Wu L, Nie J, Lin B, Tang S, Zhang Y, Wang G, Zhang C, Han J, Xu B, Liu L, Gong K, Zheng T. | 11/9/2019 |
| Study demonstrates that the expression of gankyrin is positively associated with disease progression, metastasis, sunitinib-resistance and poor prognosis of renal cell carcinoma (RCC) patients. Moreover, gankyrin expression is an independent risk factor for overall survival and progression-free survival of RCC patients. | Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma.
Wang C, Li Y, Chu CM, Zhang XM, Ma J, Huang H, Wang YN, Hong TY, Zhang J, Pan XW, Zheng JC, Jiang N, Hu CY, Ma X, Sun YH, Cui XG., Free PMC Article | 06/15/2019 |
| Gankyrin is mainly overexpressed in high grade prostate tumors so it may have a significant role in prostate cancer progress | Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer.
Riahi MM, Sistani NS, Zamani P, Abnous K, Jamialahmadi K. | 04/27/2019 |
| KIFC1 induced epithelial-to-mesenchymal transition and HCC metastasis both in vitro and in vivo. This tumorigenic effect depended on gankyrin; inhibiting gankyrin activity reversed EMT via activation of TWIST1. | KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
Han J, Wang F, Lan Y, Wang J, Nie C, Liang Y, Song R, Zheng T, Pan S, Pei T, Xie C, Yang G, Liu X, Zhu M, Wang Y, Liu Y, Meng F, Cui Y, Zhang B, Liu Y, Meng X, Zhang J, Liu L., Free PMC Article | 04/27/2019 |
| miR-214 functions as a tumor suppressor in PTC cells by targeting PSMD10, suggesting that it may be a potential target for the treatment of PTC. | miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10.
Liu F, Lou K, Zhao X, Zhang J, Chen W, Qian Y, Zhao Y, Zhu Y, Zhang Y., Free PMC Article | 03/9/2019 |
| gankyrin alleviates oxidative stress via mTORC1 pathway activation. | Gankyrin Drives Malignant Transformation of Gastric Cancer and Alleviates Oxidative Stress via mTORC1 Activation.
Huang B, Cai W, Wang Q, Liu F, Xu M, Zhang Y., Free PMC Article | 12/22/2018 |
| the pro-malignant effects of Gankyrin in CRC cells | Transcriptomic analysis reveals the underlying pro-malignant functions of Gankyrin for colorectal cancer via affecting tumor necrosis factor pathway.
Xu B, Li S, Lv W, Wang Y, Li X, Zhang L, Lin J. | 11/17/2018 |
| Low Gankyrin expression is associated with drug resistance in Breast Cancer. | Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
Taheri T, Jamialahmadi K, Khadijeh F., Free PMC Article | 08/18/2018 |
| the results demonstrated that the lentivirus-mediated shRNA vector-based RNAi expression system is an efficient method to silence PSMD10 gene expression in the MM RPMI-8226 cell line. It may provide a basis to study the role of PSMD10 in tumor cells, and may be a reliable gene therapy strategy in the clinic | Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI‑8226 multiple myeloma cells.
Du S, Qin W, Leng H, Chen Z, Zhang T., Free PMC Article | 04/7/2018 |
| Gankyrin sustains PI3K/GSK-3beta/beta-catenin signal activation and promotes an aggressive colorectal cancer phenotype and disease progression. | Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
He F, Chen H, Yang P, Wu Q, Zhang T, Wang C, Wei J, Chen Z, Hu H, Li W, Cao J., Free PMC Article | 02/24/2018 |
| PSMD10/gankyrin has a role in inducing autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression | PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression.
Luo T, Fu J, Xu A, Su B, Ren Y, Li N, Zhu J, Zhao X, Dai R, Cao J, Wang B, Qin W, Jiang J, Li J, Wu M, Feng G, Chen Y, Wang H., Free PMC Article | 01/6/2018 |
| we conclude that FXR-Gank-TSPs-Stem cells pathway is a key determinant of liver cancer in animal models and in pediatric liver cancer. Our data provide a strong basis for development of FXR-Gank-based therapy for treatment of patients with hepatoblastoma | FXR-Gankyrin axis is involved in development of pediatric liver cancer.
Valanejad L, Lewis K, Wright M, Jiang Y, D'Souza A, Karns R, Sheridan R, Gupta A, Bove K, Witte D, Geller J, Tiao G, Nelson DL, Timchenko L, Timchenko N., Free PMC Article | 10/7/2017 |
| p28 assists the proteolytic core particle to select a specific conformation of the ATPase ring for regulatory particle engagement and is released in a shoehorn-like fashion in the last step of the chaperone-mediated proteasome assembly. | Conformational Landscape of the p28-Bound Human Proteasome Regulatory Particle.
Lu Y, Wu J, Dong Y, Chen S, Sun S, Ma YB, Ouyang Q, Finley D, Kirschner MW, Mao Y., Free PMC Article | 09/30/2017 |
| gankyrin regulates HIF-1alpha protein stability and cyclin D1 expression, ultimately mediating FSH-driven ovarian cancer cell proliferation | Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.
Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, Chen X, Yu Y, Bast RC, Zhang Z, Feng Y, Zheng W. | 09/2/2017 |
| The positive feedback regulation involving gankyrin and Nrf2 modulates a series of antioxidant enzymes, thereby lowering intracellular ROS and conferring a steadier intracellular environment, which prevents mitochondrial damage and cell death induced by excessive oxidative stress. | Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma.
Yang C, Tan YX, Yang GZ, Zhang J, Pan YF, Liu C, Fu J, Chen Y, Ding ZW, Dong LW, Wang HY., Free PMC Article | 07/22/2017 |
| Gankyrin enhanced gastric cancer cell proliferation by regulating cell cycle-related proteins and by activating PI3K/AKT signaling pathway. Gankyrin played an important role in gastric carcinogenesis and could be a potential effective therapeutic target for enhancing chemosensitivity to 5-fluorouracil and cisplatin. | Gankyrin promotes the proliferation of gastric cancer and is associated with chemosensitivity.
Zeng YC, Sun D, Li WH, Zhao J, Xin Y. | 07/15/2017 |
| gankyrin is an oncoprotein that can be modified by small molecules in tumor cell lines | Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.
Chattopadhyay A, O'Connor CJ, Zhang F, Galvagnion C, Galloway WR, Tan YS, Stokes JE, Rahman T, Verma C, Spring DR, Itzhaki LS., Free PMC Article | 04/1/2017 |